THERAPY DOSSIER · th-b0e16d79e37d

Tomentin (5-hydroxy-6,7-dimethoxycoumarin) and sphaeralcic acid from Sphaeralcea angustifolia cell suspension cultures

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04511195 ↗PHASE2unknown

Phytopharmaceutical with Sphaeralcea angustifolia extract as topical treatment of knee osteoarthritis

Knee Osteoarthritis

Enrolment: 100 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24488717 ↗2014Reported benefit

Sphaeralcic acid and tomentin, anti-inflammatory compounds produced in cell suspension cultures of Sphaeralcea angustifolia.

MouseChemical/toxinICRMaleLocal application to the ear in the phorbol ester model; the route for the 45 mg/kg dose is not stated45 mg/kg in the carrageenan footpad model; 225 mM per ear f…

Model: Acute inflammation models: lambda-carrageenan-induced footpad oedema and phorbol ester-induced auricular oedema

At 45 mg/kg tomentin inhibited carrageenan footpad oedema by 58 per cent and sphaeralcic acid by 66 per cent; locally applied tomentin at 225 mM per ear and sphaeralcic acid at 174 mM per ear inhibited phorbol ester auricular oedema by 57 and 86 per cent respectively.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…